Caloric Restriction Substantially Improves Glucose Regulation in Mice With Hnf1a-Deficient Beta-Cells

Shayla Sharmine1, Thomas Aga Legøy1, Lucas Unger1

  • 1Mohn Research Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway.

PubMed
Abstract

Insights

Diet significantly impacts HNF1A-MODY by affecting insulin-secreting beta-cells. Caloric restriction improves blood glucose, while high-fat diets worsen defects, revealing diet as a key therapeutic target for this diabetes form.

Area of Science:

  • Endocrinology and Metabolism
  • Molecular Biology
  • Genetics

Background:

  • Hepatocyte Nuclear Factor 1-alpha Maturity-Onset Diabetes of the Young (HNF1A-MODY) shows incomplete penetrance, suggesting environmental and genetic factors influence its onset and progression.
  • The specific impact of environmental factors, like diet, on HNF1A-MODY remains largely unexplored.

Purpose of the Study:

  • To investigate the influence of diet on islet and insulin-secreting beta-cells in the context of HNF1A mutations.
  • To explore the molecular mechanisms underlying diet-induced changes in HNF1A-deficient beta-cells.

Main Methods:

  • Utilized transgenic mice with Hnf1a mutations in beta-cells, subjected to high-fat and caloric restriction diets.
  • Employed in vitro stem cell islets with HNF1A mutations for human validation.
  • Performed physiological tests, immunofluorescence, proteomics, and transcriptomics (bulk and single-cell).

Main Results:

  • Hnf1a-deficient beta-cells are highly sensitive to dietary cues.
  • High-fat diets worsened glucose regulation, while caloric restriction improved it in vivo without altering islet structure.
  • Proteomic analysis revealed alterations in metabolic and growth regulators like Chrebp/Mlxipl and Acly in Hnf1a-deficient beta-cells.

Conclusions:

  • Diet plays a crucial role in the function of HNF1A-deficient beta-cells.
  • These findings open new therapeutic avenues, particularly diet management strategies for HNF1A-MODY.

Related Concept Videos

Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.7K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
6.3K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.1K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
763